After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through its $3.9 billion ...

Merck KGaA (ETR:MRK) executives told investors the company delivered “solid” organic growth in 2025 despite a challenging ...

Q4 2025 Press Conference Call March 5, 2026 4:00 AM ESTCompany ParticipantsAxel LoberBelén Garijo López - Chair of Executive Board ...

By Ludwig Burger and Patricia Weiss FRANKFURT, March 5 (Reuters) - Germany's Merck KGaA projected 2026 adjusted operating profit to slip by as much as 9.8%, hurt by negative currency effects and the ...

In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on ...

Merck KGaA expects its 2026 adjusted operating profit to decrease by up to 4%, excluding currency effects, according to its latest statement.

White House messaging appeared to quickly influence medical practice ...

Find insight on Merck KGaA and Granules India in the latest Market Talks covering the health care sector.

Investing.com -- Merck KGaA (ETR:MRCG) on Thursday warned adjusted operating profit margins would shrink in 2026 as patent ...

Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple ...

Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. | Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug ...

Did you know neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) is a rare genetic disorder that can cause tumors ...